Arcellx's cell therapy is on hold after patient death in multiple myeloma trial
Arcellx said its autologous cell therapy was put on hold last Friday after the death of a recent patient in a trial testing the biotech’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
